SCHEMBL4678499

SCHEMBL4678499

O=C(C=C(O)c1nc[nH]n1)c1ccc(Cc2ccccc2C(F)(F)F)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.35
AR P10275 1/20 0.34
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
LMNA P02545 2/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
POLQ O75417 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
SNCA P37840 1/20 0.33
NTRK1 P04629 1/20 0.32
MAPT P10636 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MAOB P27338 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677051 0.87 TAAR1 (0.37) ALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL4675323 0.85 PTGER1 (0.37) ALDH1A1LMNAHPGDMAPT
SCHEMBL4678961 0.84 PTGER1 (0.36) ALDH1A1TDP1HTTSMN1; SMN2MAPT
SCHEMBL4672746 0.84 PTPN11 (0.45) KDM4EALDH1A1TDP1LMNAHPGD
SCHEMBL4677797 0.84 SRD5A2 (0.36) NR3C2FFAR1KDM4EALDH1A1LMNA
SCHEMBL4674095 0.83 AR (0.36) NR3C2ARFFAR1FFAR4KDM4E
SCHEMBL4678595 0.83 ALDH1A1 (0.39) NR3C2KDM4EALDH1A1TDP1LMNA
SCHEMBL4676336 0.83 AR (0.35) NR3C2ARFFAR1FFAR4KDM4E
SCHEMBL4677062 0.82 LMNA (0.41) NR3C2FFAR1FFAR4KDM4EALDH1A1
SCHEMBL4673057 0.81 AR (0.35) NR3C2ARFFAR1FFAR4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NR3C2 221/4885AR 10/4885FFAR1 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.